Innovative contracts can offer significant benefits for stakeholders delivering novel drugs and medical products to patients — but they require resources to design and implement. This Implementation Brief outlines key … Read More
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States
New open access policy analysis from Institute for Clinical and Economic Review (ICER) and NEWDIGS Initiative at Tufts Medical Center analyzes the challenges and potential policy options for paying for … Read More
Implementation Brief: Innovative contracting 101
This brief provides an introduction to innovative contracts, or value-based contracts, which may be used to facilitate access to innovative, high-cost treatments. These contracts can address uncertainty around treatments and … Read More
Mara Palm joins NEWDIGS
We are pleased to announce that Marisha (Mara) Palm, MSC, PhD has joined our research team at the Center for Biomedical System Design. Mara has played a leadership role in our work … Read More
Implementation Brief: Access considerations for innovative treatments
This brief offers a checklist of key steps that different stakeholders should consider to ensure patients have access to innovative treatments. These therapies present unique challenges for different stakeholders and … Read More
NEWDIGS leaders named to Illinois SCD Advisory Council
Our Strategic Director Mark Trusheim was appointed by Illinois Governor Pritzker to the Advisory Council on Financing and Access to Sickle Cell Disease Treatment and Other High-Cost Drugs & Treatment. Rena … Read More
Implementation Brief: Key terms for payment innovation
This brief provides definitions of key terms that are often used in discussions about designing and implementing innovative payment solutions. It offers an overview of solution models, types of risk, … Read More
ISPOR 2024 panel recap: Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of a Monte Carlo Projection
Atlanta, GA – On Monday, May 6, NEWDIGS community members presented a panel discussion at the annual ISPOR meeting, “Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of … Read More
Implementation Brief: Considerations for developers in applying the Multiple Best Price (MBP) rule to improve access to novel therapies
This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect … Read More
BioCentury OpEd: Biomedical Innovation Requires Health System Innovation
New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More